Mayne Pharma Group (MYX) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with a welcome to shareholders, proxies, attorneys, and board members, both in-person and online.

• Meeting commenced at 10:00am Melbourne Time on 18 June 2025, focusing on improving patient access to life-enhancing medications.

• Chair Frank Condella introduced the board and executive team, including CEO Shawn Patrick O'Brien and several non-executive directors.

• The sole agenda item was the proposed acquisition of all shares by Cosette Australia Bidco Pty Ltd via a scheme of arrangement.

• The meeting was held as a hybrid event, allowing real-time participation and voting.

Shareholder proposals

• The only business was the scheme resolution regarding the acquisition by Cosette.

• Scheme resolution proposed approval of a scheme of arrangement between the company and its ordinary shareholders, subject to court approval.

Q&A with stakeholders

• Shareholders could ask questions in person or online, with moderation to avoid repetition.

• Stakeholders were provided instructions for submitting written or verbal questions during the meeting.

• Questions addressed the choice of the New South Wales Supreme Court, FIRB approval status, and proxy participation.

• FIRB approval is still being pursued and Cosette is actively engaged in the process.

• Participation in proxy voting exceeded the previous issue.